Somnomed Ltd has released a press release.
Half Year Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Somnomed
- Core revenue growth up 19% in Q2
- Strong North American revenue growth in Q1
- North American direct revenues up 31% in Q4
- 500,000 patients treated worldwide
- Core revenue growth up 9% in Q3
Later from Somnomed
- Pause in Trading
- Suspension from Official Quotation
- Trading Update and Entitlement Offer
- Results of Institutional Offer
- Reinstatement to Official Quotation
Follow Somnomed into a list and get an email when it puts out news.
Follow Somnomed